Finding a Better Antifungal Agent for Lung Transplant Patients

Date: Jul 16, 2015

Because human airways are open to airborne fungal spores and pathogens, lung transplant patients are especially susceptible to infections, a major cause of post-transplant disease and even death. A reliable means of preventing fungal infection in lung transplant patients is the drug posaconazole. Even though it serves well for preventing infection, the oral suspension has poor bioavailability, or absorption into the bloodstream, and patients need to have low gastric pH and high dietary fat intake for adequate systemic exposure.

In November 2013, the FDA approved a new formulation, a posaconazole extended-release tablet, which doctors at Emory Transplant Center began prescribing to patients because of its predictable absorption and improved systemic exposure.

“The purpose of the research study was to compare the oral suspension with the extended-release tablets and determine the likelihood of achieving therapeutic posaconazole levels, which provides the optimal benefit for patients,” says Michael Hurtik, clinical pharmacist for the heart and lung transplant programs, who was the first author on the study. He and the team’s pulmonologists, including Emory Lung Transplant Program medical director, Dr. David Neujahr, looked at data from a cohort of Emory Transplant Center patients who received single or bilateral lung transplantation between January 2013 and October 2014, and were treated for four months post-transplant with nebulized amphotericin and posaconazole oral suspension or the extended-release tablets.

The results showed that the use of the new posaconazole extended-release tablets resulted in therapeutic blood levels for fungal prophylaxis more often (87% of patients) than the oral suspension formulation (39%). The lung transplant patients studied also tolerated the tablets well and no one needed a dose reduction or discontinuation of the medication. This study was successful in finding a better antifungal agent for our lung transplant patients that also provides the most optimal health benefit.

Learn more about the Emory Transplant Center.


Related Posts

  • transplant center lean methodology
    Using Lean methodology, Emory Transplant Center identifies quality issues and finds effective solutions to improve patient care. Learn more.
  • Number three in a circle in blue neon light on a black background
    Emory Transplant Center performs first-ever triple organ transplant procedure in Georgia, involving the transplantation of a heart, liver and kidney.
  • Improve Access to Kidney Transplants
    The RaDIANT Study at Emory Transplant Center collects regional and national data to help understand disparities in the kidney transplant process.

Emory Health Source Newsletter

For more stories and health and wellness tips, sign up for our monthly newsletter.

 

Sign Up


Recent Posts